U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT07602569) titled 'A Prospective Study on the Diagnosis of Malignant Tumors With 18F-FGIn PET/CT' on May 16.
Brief Summary: Glutamine is a crucial nutrient for cancer cell growth, and its metabolism is frequently dysregulated in malignancies. 18F-FGln is a PET tracer that targets this altered glutamine metabolism. However, there are currently limited studies on the diagnostic value of 18F-FGln PET/CT in various types of cancer. Therefore, this prospective study was conducted to investigate the value of 18F-FGln PET/CT in patients with various types of malignant tumors.
Study Start Date: Oct. 20, 2025
Study Type: OBSERVATIONAL
Condition:
Cancer (Wit...